275 related articles for article (PubMed ID: 23301767)
1. Substituted 4-(thiazol-5-yl)-2-(phenylamino)pyrimidines are highly active CDK9 inhibitors: synthesis, X-ray crystal structures, structure-activity relationship, and anticancer activities.
Shao H; Shi S; Huang S; Hole AJ; Abbas AY; Baumli S; Liu X; Lam F; Foley DW; Fischer PM; Noble M; Endicott JA; Pepper C; Wang S
J Med Chem; 2013 Feb; 56(3):640-59. PubMed ID: 23301767
[TBL] [Abstract][Full Text] [Related]
2. Comparative structural and functional studies of 4-(thiazol-5-yl)-2-(phenylamino)pyrimidine-5-carbonitrile CDK9 inhibitors suggest the basis for isotype selectivity.
Hole AJ; Baumli S; Shao H; Shi S; Huang S; Pepper C; Fischer PM; Wang S; Endicott JA; Noble ME
J Med Chem; 2013 Feb; 56(3):660-70. PubMed ID: 23252711
[TBL] [Abstract][Full Text] [Related]
3. Structure-based design of highly selective 2,4,5-trisubstituted pyrimidine CDK9 inhibitors as anti-cancer agents.
Shao H; Foley DW; Huang S; Abbas AY; Lam F; Gershkovich P; Bradshaw TD; Pepper C; Fischer PM; Wang S
Eur J Med Chem; 2021 Mar; 214():113244. PubMed ID: 33581551
[TBL] [Abstract][Full Text] [Related]
4. 2-Anilino-4-(thiazol-5-yl)pyrimidine CDK inhibitors: synthesis, SAR analysis, X-ray crystallography, and biological activity.
Wang S; Meades C; Wood G; Osnowski A; Anderson S; Yuill R; Thomas M; Mezna M; Jackson W; Midgley C; Griffiths G; Fleming I; Green S; McNae I; Wu SY; McInnes C; Zheleva D; Walkinshaw MD; Fischer PM
J Med Chem; 2004 Mar; 47(7):1662-75. PubMed ID: 15027857
[TBL] [Abstract][Full Text] [Related]
5. Novel compounds with potent CDK9 inhibitory activity for the treatment of myeloma.
Czudor Z; Balogh M; Bánhegyi P; Boros S; Breza N; Dobos J; Fábián M; Horváth Z; Illyés E; Markó P; Sipos A; Szántai-Kis C; Szokol B; Őrfi L
Bioorg Med Chem Lett; 2018 Feb; 28(4):769-773. PubMed ID: 29329658
[TBL] [Abstract][Full Text] [Related]
6. Synthesis, structure-activity relationship and biological evaluation of 2,4,5-trisubstituted pyrimidine CDK inhibitors as potential anti-tumour agents.
Shao H; Shi S; Foley DW; Lam F; Abbas AY; Liu X; Huang S; Jiang X; Baharin N; Fischer PM; Wang S
Eur J Med Chem; 2013; 70():447-55. PubMed ID: 24185375
[TBL] [Abstract][Full Text] [Related]
7. Meriolins (3-(pyrimidin-4-yl)-7-azaindoles): synthesis, kinase inhibitory activity, cellular effects, and structure of a CDK2/cyclin A/meriolin complex.
Echalier A; Bettayeb K; Ferandin Y; Lozach O; Clément M; Valette A; Liger F; Marquet B; Morris JC; Endicott JA; Joseph B; Meijer L
J Med Chem; 2008 Feb; 51(4):737-51. PubMed ID: 18232649
[TBL] [Abstract][Full Text] [Related]
8. Discovery of 5-(2-(phenylamino)pyrimidin-4-yl)thiazol-2(3H)-one derivatives as potent Mnk2 inhibitors: synthesis, SAR analysis and biological evaluation.
Diab S; Teo T; Kumarasiri M; Li P; Yu M; Lam F; Basnet SK; Sykes MJ; Albrecht H; Milne R; Wang S
ChemMedChem; 2014 May; 9(5):962-72. PubMed ID: 24677692
[TBL] [Abstract][Full Text] [Related]
9. Discovery of coumarin derivatives as potent and selective cyclin-dependent kinase 9 (CDK9) inhibitors with high antitumour activity.
Xu J; Li H; Wang X; Huang J; Li S; Liu C; Dong R; Zhu G; Duan C; Jiang F; Zhang Y; Zhu Y; Zhang T; Chen Y; Tang W; Lu T
Eur J Med Chem; 2020 Aug; 200():112424. PubMed ID: 32447197
[TBL] [Abstract][Full Text] [Related]
10. Design, synthesis, and biological evaluation of 2,6,7-substituted pyrrolo[2,3-d]pyrimidines as cyclin dependent kinase inhibitor in pancreatic cancer cells.
Shi X; Quan Y; Wang Y; Wang Y; Li Y
Bioorg Med Chem Lett; 2021 Feb; 33():127725. PubMed ID: 33316409
[TBL] [Abstract][Full Text] [Related]
11. Design, synthesis and anticancer evaluation of selective 2,4-disubstituted pyrimidine CDK9 inhibitors.
Xu Z; Zhang B; Liu Z; Gou S
Eur J Med Chem; 2022 Dec; 244():114875. PubMed ID: 36332552
[TBL] [Abstract][Full Text] [Related]
12. Novel Pyrazolo[3,4-d]pyrimidines as Potential Cytotoxic Agents: Design, Synthesis, Molecular Docking and CDK2 Inhibition.
Maher M; Kassab AE; Zaher AF; Mahmoud Z
Anticancer Agents Med Chem; 2019; 19(11):1368-1381. PubMed ID: 31038080
[TBL] [Abstract][Full Text] [Related]
13. Single step synthesis of new fused pyrimidine derivatives and their evaluation as potent Aurora-A kinase inhibitors.
Shaaban MR; Saleh TS; Mayhoub AS; Farag AM
Eur J Med Chem; 2011 Sep; 46(9):3690-5. PubMed ID: 21664013
[TBL] [Abstract][Full Text] [Related]
14. Design, synthesis, and biological evaluation of dinaciclib and CAN508 hybrids as CDK inhibitors.
Odeh DM; Allam HA; Baselious F; Mahmoud WR; Odeh MM; Ibrahim HS; Abdel-Aziz HA; Mohammed ER
Drug Dev Res; 2024 May; 85(3):e22193. PubMed ID: 38685605
[TBL] [Abstract][Full Text] [Related]
15. New insights in the structure-activity relationships of 2-phenylamino-substituted benzothiopyrano[4,3-d]pyrimidines as kinase inhibitors.
Salerno S; García-Argáez AN; Barresi E; Taliani S; Simorini F; La Motta C; Amendola G; Tomassi S; Cosconati S; Novellino E; Da Settimo F; Marini AM; Via LD
Eur J Med Chem; 2018 Apr; 150():446-456. PubMed ID: 29547832
[TBL] [Abstract][Full Text] [Related]
16. A novel pyrazolo[1,5-a]pyrimidine is a potent inhibitor of cyclin-dependent protein kinases 1, 2, and 9, which demonstrates antitumor effects in human tumor xenografts following oral administration.
Heathcote DA; Patel H; Kroll SH; Hazel P; Periyasamy M; Alikian M; Kanneganti SK; Jogalekar AS; Scheiper B; Barbazanges M; Blum A; Brackow J; Siwicka A; Pace RD; Fuchter MJ; Snyder JP; Liotta DC; Freemont PS; Aboagye EO; Coombes RC; Barrett AG; Ali S
J Med Chem; 2010 Dec; 53(24):8508-22. PubMed ID: 21080703
[TBL] [Abstract][Full Text] [Related]
17. Synthesis, anticancer evaluation, and molecular docking studies of some novel 4,6-disubstituted pyrazolo[3,4-d]pyrimidines as cyclin-dependent kinase 2 (CDK2) inhibitors.
Cherukupalli S; Chandrasekaran B; Kryštof V; Aleti RR; Sayyad N; Merugu SR; Kushwaha ND; Karpoormath R
Bioorg Chem; 2018 Sep; 79():46-59. PubMed ID: 29753773
[TBL] [Abstract][Full Text] [Related]
18. Design, Synthesis, and Biological Evaluation of Substituted Pyrimidines as Potential Phosphatidylinositol 3-Kinase (PI3K) Inhibitors.
Zhang JQ; Luo YJ; Xiong YS; Yu Y; Tu ZC; Long ZJ; Lai XJ; Chen HX; Luo Y; Weng J; Lu G
J Med Chem; 2016 Aug; 59(15):7268-74. PubMed ID: 27427973
[TBL] [Abstract][Full Text] [Related]
19. Design, synthesis and biological evaluation of benzyl 2-(1H-imidazole-1-yl) pyrimidine analogues as selective and potent Raf inhibitors.
Kim M; Lee J; Jung K; Kim H; Aman W; Ryu JS; Hah JM
Bioorg Med Chem Lett; 2014 Aug; 24(15):3600-4. PubMed ID: 24878193
[TBL] [Abstract][Full Text] [Related]
20. Discovery of 4-(((4-(5-chloro-2-(((1s,4s)-4-((2-methoxyethyl)amino)cyclohexyl)amino)pyridin-4-yl)thiazol-2-yl)amino)methyl)tetrahydro-2H-pyran-4-carbonitrile (JSH-150) as a novel highly selective and potent CDK9 kinase inhibitor.
Wang B; Wu J; Wu Y; Chen C; Zou F; Wang A; Wu H; Hu Z; Jiang Z; Liu Q; Wang W; Zhang Y; Liu F; Zhao M; Hu J; Huang T; Ge J; Wang L; Ren T; Wang Y; Liu J; Liu Q
Eur J Med Chem; 2018 Oct; 158():896-916. PubMed ID: 30253346
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]